Fritextsökning
Artiklar per år
Innehållstyper
-
Nya blodtrycksgener identifierade
Åtta hittills okända gener som påverkar blodtrycket har kartlagts i en stor internationell studie.
-
Biotage i patenttvist om labbutrustning
Det svenska bolaget Biotage har fått en stämningsansökan emot sig i USA. -Motparten saknar fog för påståendet, säger Biotages vd Torben Jørgensen.
-
Tigran får fransk order
Genom partnerbolaget Advanced Medical Products har Tigran tagit i sin hittills största order sedan försäljningsstarten ifjol.
-
Biologer blir hedersdoktorer
Till vardags har de tre världsledande forskarna sin hemmabas i Tokyo, San Diego och vid Sahlgrenska Instutet. I maj blir blir de promoverade till hedersdoktorer vid Chalmers Tekniska Högskola.
-
50 får gå från Pfizer - vd slutar
Pfizers vd Niklas Prager lämnar bolaget i samband med en omorganisation som träder i kraft i april.
-
Orexo mot nya marknader
Smärtbehandlingen Abstral har godkänts för försäljning i Frankrike och Spanien. Det ger Orexo rätt till en milstolpeutbetalning.
-
Instrument för skräddarsydd behandling snart här
En apparat stor som en mobiltelefon kan komma att revolutionera förskrivningen av läkemedel.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
BREAKING